Showing results (431-440 of 470) with videos related to

Sort By:
Pageof 47
Annals of the Rheumatic Diseases|June 8, 2010
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
Arthritis and Rheumatism|September 30, 2008
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trialAllen D Sawitzke, Helen Shi, Martha F Finco, et al.
JCI Insight|January 26, 2021
CD6 is a target for cancer immunotherapyJeffrey H Ruth, Mikel Gurrea-Rubio, Kalana S Athukorala, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 24, 2024
Identification and validation of a threshold for early posttransplant bronchoalveolar fluid hyaluronan that distinguishes lung recipients at risk for chronic lung allograft dysfunctionJamie L Todd, Jeremy M Weber, Francine L Kelly, et al.
The European Respiratory Journal|November 27, 2025
Reduced lung fluid club cell secretory protein informs chronic lung allograft dysfunction riskJeeyon G Rim, Jeremy M Weber, Megan L Neely, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2020
Risk Factors for Acute Rejection in the First Year after Lung Transplant. A Multicenter StudyJamie L Todd, Megan L Neely, Heather Kopetskie, et al.
Pediatric Rheumatology Online Journal|August 31, 2012
Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodologyNorman T Ilowite, Christy I Sandborg, Brian M Feldman, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 11, 2021
Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter studyMichael Y Shino, Ning Li, Jamie L Todd, et al.
The Lancet. Respiratory Medicine|October 26, 2013
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialLisa Young, Hye-Seung Lee, Yoshikazu Inoue, et al.
The European Respiratory Journal|March 9, 2019
Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosisNishant Gupta, Hye-Seung Lee, Lisa R Young, et al.
Pageof 47